Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Chemicals & Petrochemicals | Small Cap
Health Score : 7.13Tatva Chintan Pharma Chem Ltd demonstrates a mixed financial performance. The company shows excellent solvency and coverage ratios, indicating it has very little debt and strong ability to meet its interest and dividend obligations. Profitability is also a strong point, characterized by high gross profit, return on capital employed, and operating and net margins. However, the company struggles with efficiency, growth, and financial ratios. Its turnover ratios are low, suggesting challenges in utilizing assets effectively, and growth metrics reveal declines in revenue, operating profit, and earnings per share. Financial ratios like adjusted EPS and capital expenditures also reflect poor performance. While the company maintains a very healthy financial position with almost no debt, its declining growth and inefficient operations raise concerns about its long-term sustainability and competitiveness in the chemical and petrochemical industry. The company's asset growth is a notable positive, but it's overshadowed by other negative trends.
Health Score : 7.13Tatva Chintan Pharma Chem Ltd demonstrates a mixed financial performance. The company shows excellent solvency and coverage ratios, indicating it has very little debt and strong ability to meet its interest and dividend obligations. Profitability is also a strong point, characterized by high gross profit, return on capital employed, and operating and net margins. However, the company struggles with efficiency, growth, and financial ratios. Its turnover ratios are low, suggesting challenges in utilizing assets effectively, and growth metrics reveal declines in revenue, operating profit, and earnings per share. Financial ratios like adjusted EPS and capital expenditures also reflect poor performance. While the company maintains a very healthy financial position with almost no debt, its declining growth and inefficient operations raise concerns about its long-term sustainability and competitiveness in the chemical and petrochemical industry. The company's asset growth is a notable positive, but it's overshadowed by other negative trends.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
96.05
Industry Median
39.73
Small Cap Median
37.95
P/E RATIO
89.27
P/B RATIO
4.81
Industry Median
2.59
Small Cap Median
2.40
P/S RATIO
7.11
Industry Median
2.52
Small Cap Median
2.34
Others
PEG RATIO
-21.36
EV/EBITDA RATIO
37.02
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1605 as on Sep 1, 2026.
Growth Score : 2.80The company's growth ratios reveal significant challenges. Declines in revenue, operating profit, and earnings per share suggest weakening performance. While asset growth is positive, it's overshadowed by other negative trends. The weighted average calculation reflects recent struggles in maintaining growth momentum. Diversification or strategic realignment may be needed to revitalize growth.
Revenue Growth RatePoorOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 44.67 | -2.3 | -7.08 | -2.79 | 32.11 |
| Operating Profit Growth Rate | 62.69 | -44.04 | 13.11 | -49.28 | 165.71 |
| Earnings Per Share (EPS) Growth | 66.22 | -52.55 | -36.79 | -81.19 | 636.89 |
| Asset Growth Rate | 108.89 | 15.35 | 7.91 | 2.08 | 20.1 |
| Net Income Growth Rate | 84.62 | -53.12 | -33.33 | -80 | 600 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | J.G.Chemicals Ltd | 9.23 | 37.26 | Neutral | 82.00 | 5.47 | 69.00 |
| 2 | Platinum Industries Ltd | 8.59 | 24.08 | Neutral | 60.00 | 9.75 | 51.00 |
| 3 | Rossari Biotech Ltd | 8.46 | 17.69 | Neutral | 286.00 | 25.79 | 149.00 |
| 4 | Fineotex Chemical Ltd | 8.39 | 52.51 | Neutral | 135.00 | 0.79 | 125.00 |
| 5 | Vidhi Specialty Food Ingredients Ltd | 8.25 | 36.16 | Neutral | 78.00 | 9.84 | 49.00 |
| 6 | Bhansali Engineering Polymers Ltd | 8.25 | 17.56 | Undervalued | 216.00 | 7.25 | 180.00 |
| 7 | Styrenix Performance Materials Ltd | 8.12 | 19.35 | Neutral | 463.00 | 180.10 | 273.00 |
| 8 | Balaji Amines Ltd | 7.71 | 46.70 | Overvalued | 265.00 | 51.09 | 169.00 |
| 9 | Tatva Chintan Pharma Chem Ltd | 7.13 | 89.27 | Highly Overvalued | 93.00 | 16.71 | 42.00 |
| 10 | Neogen Chemicals Ltd | 6.69 | 197.61 | Highly Overvalued | 137.00 | 17.15 | 29.00 |
| 11 | Laxmi Organic Industries Ltd | 6.17 | 57.66 | Neutral | 171.00 | 2.86 | 79.00 |
| 12 | Yasho Industries Ltd | 6.09 | 203.81 | Neutral | 143.00 | 17.81 | 25.00 |
| 13 | Camlin Fine Sciences Ltd | 5.80 | 70.93 | Neutral | 107.00 | -1.72 | 24.00 |
| 14 | NOCIL Ltd | 5.27 | 50.94 | Neutral | 101.00 | 3.84 | 56.00 |
| 15 | Chemplast Sanmar Ltd | 4.81 | -9.62 | Neutral | 198.00 | -63.46 | -280.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤24th Jan 26
Q3 FY26 Earnings Conference Call
BULLISH SENTIMENT
Quarterly Report⬤21st Jan 26
Quarterly Financial Results Q3 FY 2025–26
BULLISH SENTIMENT
Tatva Chintan Pharma Chem Ltd. is a specialty chemical manufacturer based in India. It is a leading producer of Structure Directing Agents (SDAs), Phase Transfer Catalysts (PTCs), electrolyte salts for supercapacitor batteries, and pharmaceutical & agrochemical intermediates, serving diverse industries globally with high-performance products.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Tatva Chintan Pharma Chem Ltd's P/E ratio (TTM) is 96.05, compared to the industry median of 39.73 and large cap median of 37.95.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Tatva Chintan Pharma Chem Ltd's P/B ratio is 4.81, compared to the industry median of 2.59 and large cap median of 2.40.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Tatva Chintan Pharma Chem Ltd's P/S ratio is 7.11, compared to the industry median of 2.52 and large cap median of 2.34.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Tatva Chintan Pharma Chem Ltd's PEG ratio is -21.36.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Tatva Chintan Pharma Chem Ltd's EV/EBITDA ratio is 37.02.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Tatva Chintan Pharma Chem Ltd's ROE is 5.38%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Tatva Chintan Pharma Chem Ltd's ROA is 9.26%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Tatva Chintan Pharma Chem Ltd's ROCE is 7%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Tatva Chintan Pharma Chem Ltd's operating margin is 18.38%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Tatva Chintan Pharma Chem Ltd's net margin is 8.30%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Tatva Chintan Pharma Chem Ltd's current ratio is 1.68.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Tatva Chintan Pharma Chem Ltd's debt-to-equity ratio is 0.01.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Tatva Chintan Pharma Chem Ltd's interest coverage ratio is 20.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Tatva Chintan Pharma Chem Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Tatva Chintan Pharma Chem Ltd's EPS is 636.89.
(Source line: "Ratios as of 08 Oct 2026, based on last traded price of ₹1605. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1996
Headquarters: Vadodara, Gujarat
Core Offerings: Structure Directing Agents (SDAs), Phase Transfer Catalysts (PTCs), Electrolyte Salts, Pharmaceutical & Agrochemical Intermediates, Performance & Specialty Chemicals
Stock Listing: NSE (TATVA), BSE (543321)
Promoter: Chintan Shah, Ajay Patel, Somani Family
1996: Incorporated as Tatva Chintan Pharma Chem Private Limited. 2007: Commissioned its first manufacturing facility at Ankleshwar, Gujarat. 2010s: Expanded product portfolio to include Phase Transfer Catalysts (PTCs) and Structure Directing Agents (SDAs). 2017: Converted to a public limited company. 2021: Successfully listed on NSE and BSE through an Initial Public Offering (IPO). Present: A globally recognized manufacturer of specialty chemicals with a focus on R&D and sustainability.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Structure Directing Agents (SDAs) | 35.4% | Operating Profit |
| Phase Transfer Catalysts (PTCs) | 32.4% | Operating Profit |
| PASC (Pharma and Agrochemical Intermediates) | 25.7% | Operating Profit |
| Electrolyte Salts & Other Specialty Chemicals | 6.5% | Operating Profit |
Structure Directing Agents (SDAs): Leading manufacturer of SDAs, critical compounds used in the synthesis of zeolites, which find applications in catalysis, adsorption, and ion exchange.
Phase Transfer Catalysts (PTCs): Offers a wide range of PTCs, essential reagents that facilitate chemical reactions between immiscible phases, widely used in various chemical synthesis processes.
PASC (Pharma and Agrochemical Intermediates): Manufactures intermediates for pharmaceutical and agrochemical industries, supporting the production of active pharmaceutical ingredients (APIs) and crop protection chemicals.
Electrolyte Salts & Other Specialty Chemicals: Produces high-purity electrolyte salts crucial for supercapacitor batteries, alongside other niche specialty chemicals for diverse industrial applications.
Chintan Shah (Managing Director): Co-founder, holds a degree in Chemical Engineering, and has extensive experience in the specialty chemicals industry, driving the company's strategic growth and innovation.
No major subsidiaries reported.
No major recent corporate actions on record.
The Tatva Chintan Pharma Chem Ltd share price today is ₹1605 on NSE (TATVA), as of 08 Oct 2026.
As of 08 Oct 2026, Tatva Chintan Pharma Chem Ltd share price is ₹1605, with previous close ₹1605. Today's range is ₹1605 to ₹1605. The 52-week range is ₹N/A to ₹N/A.
As of today, Tatva Chintan Pharma Chem Ltd's market cap is ₹3,595.2 crore (Small Cap).
Tatva Chintan Pharma Chem Ltd's current P/E ratio is 96.05, compared to the CHEMICALS & PETROCHEMICALS sector average of 33.50.
Tatva Chintan Pharma Chem Ltd's current P/B ratio is 4.81.
Tatva Chintan Pharma Chem Ltd's current dividend yield is N/A. Last dividend of ₹2.00 per share was declared on 28-May-2024.
Tatva Chintan Pharma Chem Ltd's EPS (TTM) is ₹636.89.
Tatva Chintan Pharma Chem Ltd. is a specialty chemical manufacturer based in India. It is a leading producer of Structure Directing Agents (SDAs), Phase Transfer Catalysts (PTCs), electrolyte salts for supercapacitor batteries, and pharmaceutical & agrochemical intermediates, serving diverse industries globally with high-performance products.
Tatva Chintan Pharma Chem Ltd is promoted by Chintan Shah, Ajay Patel, Somani Family, holding 72.02% as of 08 Oct 2026.
Tatva Chintan Pharma Chem Ltd is listed on NSE (TATVA) and BSE (543321). Its next quarterly results are expected on August 2024.
Return on Assets (ROA)